Abstract
Introduction
LL37 human cathelicidine is an antimicrobial and immunomodulatory peptide of the innate immunity released in a wide range of inflammatory diseases (1, 2) . LL37 exhibits an immune regulatory effect involving both the innate and acquired immune response (3) . Thus LL37 was reported to regulate interferon gamma (IFN-), a pivotal cytokine of T helper cell type 1 (Th1) inflammatory response (4, 5) . LL37 also exhibits an immune modulating effect on myeloid dendritic cells, the innate immune key cells in orchestrating the Th1 acquired response (6) Thus depending on the exposure time and cytokine concentration, LL37 could act as either a Th1-polarized co-stimulatory molecule or as a Th1 inhibitory molecule (7, 8) . The modulation of the immune response requires low LL37 concentrations (9) and it was previously studied in several inflammatory diseases (10) . The LL37 peptide also displays a broad antimicrobial spectrum due to membrane disruption mechanisms and microbial growth inhibition. Its antibacterial activity was documented in some infections (2) including sepsis (11) and tuberculosis (12) . In vitro studies also confirmed its antiviral potential (13) but the available data on the antiviral activity of LL37 against hepatitis viruses remains insufficient. Nevertheless LL37 appears to play a significant role in bile acid synthesis and its ability to bind and neutralize the heparan sulphate (14) , an HCV receptor or the purinergic P2X7 receptor (15) expressed in hepatocytes 16 P2X7 receptor activation was documented to be critical in the outcome of the inflammatory response (17) including in HBV and HDV hepatitis (18) or autoimmune liver diseases (19) . Taking into account the widespread expression of LL37 peptide in the liver epithelia as well as its antiviral and inflammatory modulating activity we hypothesized that LL37 could also take part in liver inflammatory injury induced by hepatitis viruses. The aim of our study was to assess the plasma concentration of cathelicidin LL37 peptide and Th1 inflammatory response in HBV, HCV and HDV infections.
Material and methods

Patients and samples
The study was performed on 87 Caucasian subjects aged 20-64 years, 33 males and 54 women, HIV negative selected at "Matei Bals" National Institute of Infectious Diseases, Bucharest, Romania. Sixty five subjects were diagnosed with chronic HCV, HBV and HDV hepatitis (CDC criteria (20) and 22 were healthy controls. Samples were collected after the informed written consent has been obtained from each patient.
Laboratory analyses
Subjects had baseline laboratory tests performed by standard hospital laboratory methods including: white blood cell count, platelets number, haemoglobin, creatinine, glycemia, alanine aminotransferease (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and ionic calcium, phosphorus, magnesium, hepatitis viral markers (Anti HCV, HbsAg, AntiHBs, HBeAg, Anti-HBe, Anti-HBc IgG/IgM, Anti-HDV), Anti-HIV. The viral load (RNA HCV, DNA HBV, RNA HDV) was detected with Real-time PCR assay (Roche Cobas TaqMan, limit of detection 45UI/mL for RNA HCV and 55 UI/mL for DNA HBV) (21) . RNA HDV was detected with TaqMan-based Real-time PCR (quantitative detection) or qualitative reverse transcription-PCR (RT-PCR assays limit of detection 20 copies /mL) at Institut für Medizinische Diagnostik Oderland, Germany. The LL-37 plasma level (expressed as ng/mL) was determined with the ELISA kit (HK 321 Human LL37 ELISA Kit, Hycult biotechnology, Uden, The Netherlands-detection range 0.1-100 ng/mL). Th1 response was interpreted according to IFN-, the CD4+, CD8+ cell count and the CD4/CD8 ratio. IFN-expressed as pg/mL was detected using ELISA kit (MaxDiscovery™ Human Interferon Gamma, Bioo Scientific, USA, assay range: 10-640 pg/mL). CD4+ and CD8+ were counted with Flow cytometry. All protocols followed the manufacturer's Instructions. Each ELISA test was run in duplicate, with mean absorbance computed from the average for 2 wells normalized to a zero calibrator well. The intra-assay CV for LL37 was <10% respectively. The inter-assays CV for LL37 was <10%.
Classification of patients with viral hepatitis
The patients with viral hepatitis were classified according to the viral etiology (HCV, HBV and HDV hepatitis) and viral load (active versus inactive hepatitis). Detectable viremia suggested active hepatitis and undetectable viremia, inactive hepatitis. The following groups were analyzed: -HCV hepatitis: 34 patients, out of which 27 with active HCV hepatitis (viral load with median values of 75000 UI/mL) and 7 with inactive hepatitis (undetectable viremia); -HBV hepatitis: 18 patients, out of which 12 were diagnosed with active HBV hepatitis (viral load with mean values 68000 UI/mL) and 6 with inactive HBV hepatitis (undetectable viremia); -HDV hepatitis: 13 patients, out of which 9 with active HDV hepatitis (detectable RNA HDV) and 4 with inactive HDV hepatitis (undetectable viremia).
Statistical analysis
Results were given as means +/-SD (standard deviation) or median. When Bartlett's test indicated that the group comparisons had equal variances Student T was performed. When the group data showed unequal variances, nonparametric Mann-Whitney was used. Correlations were evaluated for statistical significance with Pearson's test. A p-value < 0.05 was considered significant. Statistical tests were performed using SPSS software (version 15).
The study was approved by "Matei Bals Institute'' Hospital Scientific and Ethical Committee. The authors declare that the followed procedures were in accordance with the ethical standards of Helsinki Declaration of 1975, as revised in 2000.
Results
The mean characteristics and laboratory values of the study subjects are illustrated in Table 1 .
The serum values of LL37, the Th1 response (defined by IFN-serum level, CD4+ and CD8+ cells count and CD4/CD8 ratio) and the respective p values are presented in the Table 2 . Considering this data we performed a comparative analysis on the level of LL37 and Th1 response involving the following groups: a) The group of total hepatitis versus healthy controls and total active hepatitis versus inactive hepatitis; b) The groups of each viral hepatitis (HCV, HBV or HDV) versus healthy controls and each group of active HCV, HBV or HDV hepatitis versus the corresponding inactive forms.
a. Comparative analysis of LL37 status and Th1 response in total hepatitis versus healthy controls and total active hepatitis versus inactive forms
The status of LL37 and Th1 response for the stated groups is represented in the Figure 1 . Significant high values of LL37 and IFN-were found in hepatitis patients versus healthy controls (p=0.045 and p=0.005 respectively). The group of active hepatitis presented a dominant Th1 response (increased IFN-, CD4+ and CD8+ cell count) compared to inactive hepatitis but the only statistical difference applied to the CD4+ cell count (p=0.023).
b. Comparative analysis of LL37 status and Th1 response in each group of HCV, HBV, and HDV hepatitis versus healthy controls and active versus inactive forms
The status of LL37 and Th1 response for the stated groups is represented in the Figure 2 .
The level of LL37 was increased in all hepatitis groups (HCV, HBV, HDV) compared to healthy controls with significance for the HCV group (p=0.0464). Moreover HCV patients presented increased levels of IFN-(p=0.0001) consistent with the significant raise of LL37. A considerable increase in LL37 level was recorded in the active group of HCV hepatitis (p=0.014) accompanied by an increased IFN-(p=0.019), CD4+ cell count (p=0.004) and CD8+ cell count (0.067). Consequently the active HCV hepatitis group presented a well defined immune profile, involving an increased serum concentration of LL37 and a dominant Th1 response. On the other hand, analysis of HBV infected patients disclosed significant increases of LL37 level in inactive forms only (p=0.009) lacking a significant Th1 response. HDV infected inactive patients displayed increased serum levels of LL37 without statistically significant results by comparison with active HDV hepatitis (p=0.377). 
Discussion
Hepatitis infections with HBV, HCV and HDV viruses are some of the most common inflammatory disorders in the world and leading causes of cirrhosis and hepatocellular carcinoma. The mechanisms behind viral persistence and liver inflammatory damage are still obscure. Clinical trials and chimpanzee experiments suggested that the final outcome in viral hepatitis directly depends on the efficient cooperation between the innate and acquired immune response (22) .The innate immune response hinders viral replication in the early stages of hepatitis infection employing NK cells, dendritic cells and also cytokines such as IFN-and IFN-. Nevertheless a subsequent strong and multispecific Th1 response is required for the clearance of hepatitis viruses (23, 24) . The absence of a sustained Th1 re- sponse facilitates the viral persistence while an uncontrolled Th1-mediated inflammation accounts for ongoing liver damage and fibrogenesis (25) . The intrahepatic recruitment of Th1 inflammatory cells is ensured by IFN-, a hallmark cytokine of both the innate and acquired immune response (26) . Hepatitis viruses were documented to inhibit the release of IFN-, thus repressing the Th1 response (27). LL37, a molecule of innate immunity regulated by vitamin D activity, exhibits in vitro an immune modulating effect on IFN-and also on Th1 acquired response (6) A high level of LL37 seems to balance an adequate inflammatory response.The enhanced activity of LL37 was particularly studied in inflammatory dermatoses. The therapeutic possibilities of LL37 were also addressed in organ transplant recipients as well as in pulmonary, urinary, intestinal or systemic infections (11, 14, 28) . No data is currently available regarding the serum level and the immunomodulating activity of LL37 in viral hepatitis. Nevertheless the LL37 immunomodulatory role and its antiviral activity observed in vitro, raise the possibility of LL37 interfering with the inflammatory injury induced in viral hepatitis infections. The aim of our study was to observe the serum level of this peptide and Th1 inflammatory response in viral B, C and D hepatitis. The study revealed the following: -The serum level of LL37 was significantly increased in all patients with viral hepatitis (138.09 ng/mL) compared to controls (97.55 ng/mL) (p=0.04). Regarding the active and inactive hepatitis groups, LL37 was significantly raised in active HCV (151.43 ng/mL, p=0.014) and inactive HBV hepatitis (174.66 ng/mL, p=0.009). The current study revealed a lower LL37 serum concentration compared to levels previously reported in bacterial infections (29, 30) but significantly higher than serum values observed in tuberculosis (49.5 ng/mL) (31). The intense chemotactic activity of LL37 (5) could also trigger the local accumulation of immune cells, releasing new amounts of LL37. Therefore it is possible that the hepatic concentration of LL37 exceeds the serum level. The variations of LL37 in active HCV and inactive HBV hepatitis were consistent with those of IFN-. However the correlation between the plasma IFN-and LL37 levels was weak (R=0.257, Pearson correlation, data not shown.). A larger patient cohort is required to estimate the correlation between these molecules. Anyway a divergent inflammatory response was observed in B and C hepatitis as to the viral replication status.
-The Th1 immune response revealed a dominant pattern in HCV active hepatitis compared to inactive hepatitis. Thus HCV active hepatitis patients recorded significantly increased values of IFN-(164.81 pg/mL, p=0.019), CD4+ cell count (923 cells/mm3, p=0.004) and CD8+ cell count (479 cells/mm3, p=0.067). Interestingly if we consider the group of total hepatitis by comparison with healthy controls, the IFN-level was increased while both CD4+ and CD8+ T cell count were decreased. This could be the result of IFN-production mainly by cells of the Innate Immune response instead of CD4+ or CD8+ lymphocytes. If this is correct, the Innate Immune response could be of considerable importance during viral replication in chronic hepatitis infections (primarily concerning HCV infections), releasing high levels of IFN-and immunomodulatory peptides such as LL37. In previous studies we have studied the level of LL37 in the HCV infection in correlation with the necroinflammatory liver activity or viral replication (32) .Results have indicated a higher level of LL37 in C hepatitis with moderate necroinflammatory activity (Fibromax A score below 2) as well as an increased level of LL37 in replicative HCV infections. At the same time no positive correlation was found in one study between the level of LL37 and the concentration of 25-hydroxy vitamin D (32) . Moreover the concentration of 25-hydroxy vitamin D in patients with HCV replicative infection was modestly correlated with hepatic inflammation but strongly correlated with the CD4+ T cell count and ionic calcium. In this previous studies the Th1 inflammatory response was only partially assessed -following the CD4 response-and only in correlation with 25-hydroxy vitamin D level. The purpose of the present study was an extensive analyses of Th1 inflammatory response (defined by the plasma level of IFN-,CD4, CD8 cells) and the LL37 peptide. Moreover the analysis was performed on HCV as well as on HBV and HDV infection. The patients with HCV replicative infection exhibited a strong correlation between LL37 and the Th1 inflammatory response. The role of LL37 appeared to be of considerable importance in the immune response against the HCV infection by comparison with vitamin D. As consequences the treatment with vitamin D as an immunomodulator in chronic hepatitis should be carefully weighed against the impact of induced LL37 on the inflammatory response. Thus an excessive concentration of LL37 could over-stimulate the Th1 response and the subsequent necrosis of hepatocytes in the HCV replicative infection. On the other hand the synthesis of LL37 retains a protective role in the HBV and HDV infection.
There are several limits of our investigation. Firstly the study was performed on a low number of patients, especially in what regards patients with HDV hepatitis. A larger group of patients could have had a more significant influence on the presented data. Secondly, our analysis was based on the serum level of LL37 and immune markers which are mostly connected to the systemic and not intrahepatic inflammatory response. The hepatic inflammatory reaction could be significant but difficult to assess.
However the immune response in viral hepatitis is only partially defined. The role of the innate immunity has been less studied and is hard to asses in vivo. In vitro studies of LL37 and hepatitis viruses (both human specific) are impeded by the lack of adequate cellular models. Moreover in vitro studies are unable to explore the dynamics of the immune response.
Our study has the advantage to investigate the correlation between LL37 and the Th1 response in patients with different viral hepatitis and different viral replication status.
Further studies on larger patient groups are required in order to asses the importance of the innate immune peptide LL37 in modulating Th1 cellular response in the viral hepatitis.
Conclusion
The increased serum levels of LL37 found in B, C, and D hepatitis suggest the importance of this innate immunity peptide in viral hepatitis. The Th1 response and LL37 level were concordant in active HCV hepatitis but diverged in other types of viral hepatitis. Further studies are needed to fully understand the active role of cathelicidin LL37 in viral hepatitis and its possible therapeutical implications.
